US · Healthcare · Biotechnology
EPS came in at -0.52 against a street estimate of -0.48 — a miss of 8.3%.
with an average price target of $27.00.
| Fund | Stake |
|---|---|
| Flagship Ventures Management, Inc. | 48.83% |
| FMR Inc | 3.29% |
| Capital World Investors | 3.28% |
| BRAIDWELL LP | 2.80% |
| JPMorgan Chase & Co | 2.30% |
| T. Rowe Price Associates, Inc. | 1.64% |
| NORGES BANK | 1.63% |
| ARCH VENTURE CORP | 1.51% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 GENERATE BIOMEDICINES, INC. (GENB) — 8-K SUMMARY HEADLINE NUMBERS • Company: Generate Biomedicines, Inc., Delaware-incorporated, trading on Nasdaq u | 2026-08-26 |
| Quarterly report · Q2 2026 GENERATE BIOMEDICINES, INC. – 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash & Marketable Securities: $457.4 million (June 30, 2026) vs. $221.5 | 2026-08-06 |
| Results announced · Q3 2026 GENERATE BIOMEDICINES INC. - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $457.4 million as of Ju | 2026-08-06 |
| Quarterly report · Q1 2026 GENERATE BIOMEDICINES, INC. — Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash position: $160.6 million cash and cash equivalents; $356.1 million i | 2026-05-07 |
| Results announced · Q2 2026 GENERATE BIOMEDICINES, INC. – Q1 2026 SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and marketable securities: $516.6 million as of March 31, 2 | 2026-05-07 |
| Charter / bylaws change · Q1 2026 GENERATE BIOMEDICINES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Generate Biomedicines, Inc. (Ticker: GENB, Nasdaq) • Filing Date: February 26, | 2026-03-02 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Generate Biomedicines, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.